Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in blood. PAI-1 is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular diseases. Plasma levels of PAI-1 are regulated on a genetic basis but, more important, is the dependence on a series of other atherosclerotic risk factors like hypertriglyceridemia, diabetes and insulin resistance. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. At least in vitro, insulin is a potent inducer of PAI-1 synthesis by human hepatic cells, and, we have recently disentangled the molecular mechanisms responsible for enhanced PAI-1 gene expression by insulin. However, clinical data fail to support a direct acute contribution of insulin in regulating circulating PAI-1 levels. Recently, it has been proposed that adipose tissue could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. It now seems reasonable to view PAI-1 as one of the factors contributing to the complex gene-environment interactions involved in the formation and dissolution of thrombi.
PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms / C. Banfi, L. Mussoni, E. Tremoli. - In: MINERVA ENDOCRINOLOGICA. - ISSN 0391-1977. - 27:3(2002 Sep), pp. 181-191.
|Titolo:||PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms|
BANFI, CRISTINA (Primo)
MUSSONI, LUCIANA (Secondo)
TREMOLI, ELENA (Ultimo)
|Parole Chiave:||Animals; Plasminogen Activators; Risk Factors; Humans; Plasminogen Activator Inhibitor 1; Cardiovascular Diseases; Fibrinolysis; Plasminogen; Diabetes Complications|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||set-2002|
|Appare nelle tipologie:||01 - Articolo su periodico|